Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages
Ilia N. Buhtoiarov(University of Wisconsin–Madison), Alexander L. Rakhmilevich(University of Wisconsin–Madison), Eric Yanke(University of Wisconsin–Madison), Paul M. Sondel(University of Wisconsin–Madison), Jon M. Wigginton(Bristol-Myers Squibb (United States)), Tatiana Buhtoiarova(University of Wisconsin–Madison), David A. Mahvi(University of Wisconsin–Madison)
Cited by 142
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k
Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma
|New England Journal of Medicine|2010|1.8k